Literature DB >> 10190292

Clinical relevance of the urokinase plasminogen activator system in breast cancer.

M P Look1, J A Foekens.   

Abstract

Until recently clinical features and the hormone-receptor status were the only factors used to select systemic (adjuvant) treatment for breast cancer patients. Other biological factors are needed as well to predict the probability of relapse and response with more certainty. The uPA-system is such a prognostic and predictive factor in breast cancer. In this review, the results of research groups that have related relapse-free survival to the quantitative levels of uPA-system proteins and/or activities are discussed. Only studies that described the results from assays on cytosols or triton extracts of breast tumours were included. The levels of uPA-system proteins help to predict the probability of relapse and response, and knowledge of the expression levels of the various components of the uPA-system may lead to new treatment modalities targeted on specific properties of the uPA-system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10190292     DOI: 10.1111/j.1699-0463.1999.tb01538.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  12 in total

Review 1.  Insulin-like growth factor binding proteins (IGFBPs) in breast cancer.

Authors:  C M Perks; J M Holly
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

2.  Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.

Authors:  Sai Murali Krishna Pulukuri; Norman Estes; Jitendra Patel; Jasti S Rao
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

3.  Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1.

Authors:  G O Hjortland; K Bjørnland; S Pettersen; S S Garman-Vik; E Emilsen; J M Nesland; O Fodstad; O Engebraaten
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

4.  Deregulated activation of matriptase in breast cancer cells.

Authors:  Christelle M Benaud; Michael Oberst; Robert B Dickson; Chen-Yong Lin
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 5.  IGF binding proteins (IGFBPs) and regulation of breast cancer biology.

Authors:  Claire M Perks; Jeff M P Holly
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-25       Impact factor: 2.673

6.  Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis.

Authors:  Sai Murali Krishna Pulukuri; Jasti S Rao
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

7.  Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease.

Authors:  J A Foekens; Ch Ries; M P Look; C Gippner-Steppert; J G M Klijn; M Jochum
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

8.  Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours.

Authors:  J H de Witte; J A Foekens; N Brünner; J J Heuvel; T van Tienoven; M P Look; J G Klijn; A Geurts-Moespot; N Grebenchtchikov; T Benraad; C G Sweep
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

9.  Poised transcription factories prime silent uPA gene prior to activation.

Authors:  Carmelo Ferrai; Sheila Q Xie; Paolo Luraghi; Davide Munari; Francisco Ramirez; Miguel R Branco; Ana Pombo; Massimo P Crippa
Journal:  PLoS Biol       Date:  2010-01-05       Impact factor: 8.029

10.  Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance.

Authors:  L-Y Luo; E P Diamandis; M P Look; A P Soosaipillai; J A Foekens
Journal:  Br J Cancer       Date:  2002-06-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.